These trends underscore a need for health organizations to adapt to macroeconomic and regulatory pressures, while prioritizing investments in safeguarding artificial intelligence (AI), cybersecurity, financial resilience, global talent solutions and workforce development.
NEW YORK, Dec. 2, 2025 /PRNewswire/ — Today, Ernst & Young LLP (EY US) unveiled eight key trends projected to shape the health sector in 2026 and beyond.
As explained by Kim Dalla Torre, EY Global and Americas Health Sector Leader, these trends show that despite tight macroeconomic and regulatory pressures, health is adapting and shifting toward digital transformation.
“As we enter 2026, the health sector is at a turning point,” said Dalla Torre. “Health leaders are facing unprecedented pressures as well as unique opportunities to evolve their business models. Tomorrow’s leaders will prioritize leveraging AI and deploying innovative talent strategies while focusing on financial resilience.”
Top EY Health sector trends for 2026:
“Payers, providers and consumers are finding themselves at the intersection of change in healthcare like no other time in history,” said Dalla Torre. “Leaning into solutions now could drive value and care models that are sustainable for everyone’s future.”
For more information, visit ey.com/health.
Media contact:
Caroline Acton
caroline.acton1@ey.com
About EY
EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.
Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.
EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multidisciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.
All in to shape the future with confidence.
EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.
About EY Consumer & Health
The rise of the empowered consumer, coupled with technology advancements and the emergence of digitally focused entrants, is changing every aspect of health and care delivery. To retain relevancy in today’s digitally focused, data-infused ecosystem, all participants in healthcare today must rethink their business practices, including capital strategy, partnering and the creation of patient-centric operating models.
The EY Consumer & Health sector architecture brings together a worldwide network of 34,000 professionals to build data-centric approaches to customer engagement and improved outcomes. We help our clients deliver on their strategic goals, design optimized operating models, and form the right partnerships so they may thrive today and succeed in the health systems of tomorrow. We work across the ecosystem to understand the implications of today’s trends, proactively finding solutions to business issues and to seize the upside of disruption in this transformative age.
SOURCE EY
TGA approval enables regional launch of Owlet’s clinically validated, award-winning infant health monitor; Owlet360™ subscription…
Concludes Distribution Agreement with Gore® for VIABIL® in the United States and Canada, Effective January…
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company…
BOSTON, Dec. 05, 2025 (GLOBE NEWSWIRE) -- A recent setback due to unexpected safety concern…
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard…
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the…